论文部分内容阅读
目的 :观察尼莫同治疗急性脑出血的最佳用药时机与疗效。方法 :应用前瞻性随机单盲方法 ,对 2 16例急性脑出血病人在起病 72h内随机分为急性期 (72h)应用尼莫同组 ,亚急性期 (7～ 10d)应用尼莫同组及对照组 ,采用神经功能缺损程度积分差及CT上血肿体积与血肿周围水肿面积为指标 ,比较 3组疗效。结果 :应用尼莫同的两组在神经功能缺损的平均减少分数及CT上血肿体积与血肿周围水肿面积减少上均优于对照组 ,且急性期应用尼莫同组在上述三项指标上均优于亚急性期应用尼莫同组。结论 :尼莫同是治疗急性脑出血的一种安全、有效的药物 ,尽早应用可提高疗效。
Objective: To observe the optimal timing and effect of nimodipine in the treatment of acute cerebral hemorrhage. Methods: A prospective, randomized, single-blind method was used to divide 2,16 patients with acute cerebral hemorrhage into two groups: nimotome group (n = 72) and nimodipine group And the control group, using the difference of neurological deficit score and CT hematoma volume and hematoma area around the edema area as an index, the efficacy of the three groups were compared. Results: Nimodipine group was better than the control group in reducing the average number of neurological deficits and the volume of hematoma on CT and the area of edema around hematoma, and in the nimodipine group, Superior to the sub-acute phase nemo group. Conclusion: Nimesulide is a safe and effective drug for the treatment of acute cerebral hemorrhage. As soon as possible, it can improve the curative effect.